Atara Biotherapeutics, Inc. - Common Stock (ATRA)

13.67
-3.77 (-21.62%)
NASDAQ · Last Trade: Jan 11th, 12:47 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As investors aggressively rotate capital out of the overextended technology giants that dominated the previous three
Via MarketMinute · January 8, 2026
Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that the Federal Reserve will remain hawkish well into the new year. While the blue-chip S&P 500 (INDEXSP: .INX) showed
Via MarketMinute · January 7, 2026
Earnings Scheduled For November 12, 2024benzinga.com
Via Benzinga · November 12, 2024
Insights into Atara Biotherapeutics's Upcoming Earningsbenzinga.com
Via Benzinga · November 11, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · October 17, 2025
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicalsbenzinga.com
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Via Benzinga · September 29, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · June 18, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 6, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 24, 2025
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programsbenzinga.com
FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.
Via Benzinga · January 21, 2025
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dipstocktwits.com
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.
Via Stocktwits · January 16, 2025
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimatesbenzinga.com
Via Benzinga · January 16, 2025
Crude Oil Down 1%; Bank of America Posts Upbeat Earningsbenzinga.com
Via Benzinga · January 16, 2025
US Stocks Edge Lower; Retail Sales Increase Less Than Expectedbenzinga.com
Via Benzinga · January 16, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 14, 2025
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earningsbenzinga.com
Via Benzinga · September 4, 2024
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?benzinga.com
Atara Biotherapeutics shares are trading higher by 20% Wednesday morning. The company announced a $36 million registered direct offering.
Via Benzinga · September 4, 2024
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · September 4, 2024
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024investorplace.com
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 12, 2024
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Via Benzinga · June 17, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · June 17, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · May 31, 2024
ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com
ATRA stock results show that Atara Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · May 7, 2024
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · April 8, 2024